Urinary tract infections (UTIs) are one of the most common infectious diseases of humans, with 36 approximately 150 million cases estimated to occur globally every year. UTIs usually start as a 37 bladder infection (cystitis), but can develop into acute kidney infection (pyelonephritis) and even 38 infection of the bloodstream (urosepsis). The high frequency of UTIs in community and nosocomial 39 settings places an enormous burden on healthcare systems worldwide. Multiple different pathogens 40 cause UTI, with uropathogenic E. coli (UPEC) the most common etiological agent. UTIs caused by 41 these pathogens are increasingly associated with antibiotic resistance, thus severely reducing 42 treatment options and significantly increasing UTI-associated morbidity and mortality. In this 43 review we present an overview of the recent advances in vaccine research targeted towards the 44 prevention of UPEC-mediated UTI. In the context of multidrug resistance, we conclude that 45 vaccination represents a viable approach for the prevention of chronic and recurrent UTI. 
5 significantly higher morbidity (up to 60.8%) than non-ESBL-producing E. coli strains (23.7%) [28] . 122
In a recent retrospective study, human and animal E. coli isolates collected from 1950 and 2002 123
were assessed for historical changes in their resistance profile to 15 antibiotics. Multidrug resistance 124 (i.e. resistance to at least 3 drug classes) increased from 7.2% during the 1950s to 63.6% during the 125 2000s [29] . These alarming trends have led to an increase in the use of second-and third-line 126 therapies, further promoting the emergence of multidrug-resistant strains and highlighting the need 127 for alternative treatment and prevention approaches. glycoproteins present on the apical surface of superficial bladder epithelial cells [33] . Type 1 147 fimbriae-facilitated adhesion is mediated specifically by FimH, a minor subunit localized at the tip 148 of the fimbrial structure [34, 35] . The use of FimH (truncated or in complex with the periplasmic 149 chaperone FimC) as a vaccine candidate has been shown to inhibit the binding of UPEC to human 150 epithelial bladder cells in vitro [36] . Moreover, systemic immunization with FimH (in combination 151 with the FimC chaperone protein) promoted a strong and long-lasting immune response that led to a 152 >99% reduction in bladder colonization in a murine model of cystitis, and prevention of kidney 153 infection over a 7-day period. Immunization with FimH also correlated with a high titer of anti-154
FimH IgG antibodies in the urine of mice [36] . Further studies using a primate model of UTI 155 revealed that immunization with FimH (in complex with FimC) led to high vaginal anti-FimH titers 156 6 and resulted in significant protection from UTI following UPEC challenge [37] fold decrease in kidney colonization in a murine model of UTI compared to control groups [70] . 234
Finally, vaccination of mice with FitA (ECOK1_3457), a putative iron receptor [71] , resulted in a 235 protection efficacy of 25% in a sepsis model [56] . Uro-Vaxom, a lyophilized lysate prepared from 18 UPEC strains and licensed for human 259 application (Galenica Group), has been tested in a double-blind randomized study of patients with 260 recurrent UTI from 52 centers and nine different countries [77] . Female patients aged 18-65 years 261 9 with at least three documented episodes of UTI in the previous year were included in the 262 investigation. Capsules containing the treated UPEC lysates were administered daily during the first 263 three months, followed by no treatment during months 4-6, and then one capsule daily during the 264 first ten days of months seven to nine. In this trial, the treated group achieved a 14.7% reduction in 265 UTI episodes compared to control group. Interestingly, after month seven, the reduction increased 266 to 43%, possibly associated with the administration of booster doses. The vaccine significantly 267 impacted on the number of recurrent UTI episodes, which were reduced by 49% in the treated 268 group compared to placebo [77] . 
